Find Funding Opportunities

The National Institute of Child Health and Human Development (NICHD). National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications from investigators willing to participate in a cooperative research network designed to reduce the incidence of hypoglycemia in children and young adults. The Diabetes Research in Children Network (DirecNet) grew out of an initiative begun in 2001. Five academic centers were selected from among respondents to a previous announcement (RFA-HD-01-009) to support a network focusing on diabetes monitoring in children. This RFA serves to expand the mission of DirecNet. The network will use new tools to evaluate factors and mechanisms contributing to hypoglycemia and will set up clinical trials to test novel therapies, prevention strategies and devices designed to focus on hypoglycemia prevention for individuals with type1 diabetes. It is anticipated that a maximum of five awards for Clinical Centers (CCs) and one award for a Data Coordinating Center (DCC) will be made. Approximately $2 million (total costs)[Direct plus Facilities and Administrative (F & A) costs] will be appropriated from the Balanced Budget Act Funds for Type 1 Diabetes. This commitment is contingent upon the availability of funds. A CC applicant may request a project period of up to five years and an annual budget for direct costs associated with base costs up to $140,000 per year. A DCC applicant may request a project period of up to five years and an annual budget up to $425,000 direct costs. In addition, the DCC should request not more than $350,000 total costs per year for the distribution of per subject/per protocol costs to the Clinical Centers for approved protocols. This funding opportunity will use the NIH Cooperative Clinical Research (U10) award mechanism for both the DCC and the CCs. Investigators may submit an application if their institution has any of the following characteristics: For-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible agencies of the Federal government. Eligible Principal Investigators include those with the experience and expertise to conduct clinical studies in type1 diabetes. Individuals with expertise in endocrinology are encouraged to apply. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. An applicant institution may submit only one application in response to this RFA.

The National Institute of Mental Health (NIMH) and its Center for Mental Health Research on AIDS as well as the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) invite applications proposing novel models of HIV-related central or peripheral nervous system damage that can be used to screen for compounds showing promise as treatments in the patient population.

The National Institute of Mental Health (NIMH) and its Center for Mental Health Research on AIDS as well as the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) invite applications proposing novel models of HIV-related central or peripheral nervous system damage that can be used to screen for compounds showing promise as treatments in the patient population.

This initiative will develop and implement a new Pathway to Independence Award Program (PI) designed to facilitate receiving an R01 award earlier in an investigators research career.The primary, long-term goal of the PI Award Program is to increase and maintain a strong cohort of new and talented, NIH-supported independent investigators.

Proteomics technologies and methods remain largely inadequate, particularly with respect to quantitative and real time measurements. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest.

Proteomics technologies and methods remain largely inadequate, particularly with respect to quantitative and real time measurements. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest.

This PA solicits applications to develop research and methods to enhance the rate of membrane protein structure determination and to determine specific membrane protein structures. Innovative methods for expression, oligomerization, solubilization, stabilization, purification, characterization, crystallization, isotopic labeling, and structure determination of unique and biologically significant membrane proteins by x-ray diffraction, nuclear magnetic resonance (NMR), electron microscopic, mass spectrometry, and other biophysical techniques are encouraged. Projects that will lead in the near term to determining the structures of biologically important membrane proteins are also encouraged.

The purpose of this FOA from NIH, CDC, and FDA is to invite eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) Phase I, Phase II, Fast-Track, and Phase II Competing Renewal grant applications through Grants.gov. SBIR Fast-Track and Phase II Competing Renewal grant applications are accepted by the NIH ONLY. This FOA will receive funds appropriated for fiscal years (FY) 2006 and 2007, the amounts for which are yet to be determined. However, the amounts set-aside by NIH, CDC, and FDA for FY 2005 SBIR awards were: NIH: $571 million; CDC: $8 million; and FDA: $800,000. There are three standard, annual submission dates for NIH, CDC, and FDA SBIR grant applications: April 1, August 1, and December 1 (May 1, September 1, and January 2 for NIH AIDS and AIDS-related applications). For planning purposes, the estimated number of SBIR awards for the FY 2006 cycles are: NIH: 950 awards; CDC: 15 awards; and FDA: 2 awards. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, Fast-Track, and Phase II Competing Renewal applications, and runs in parallel with a FOA of identical scientific scope, PA-06-121, that solicits NIH applications under the Small Business Technology Transfer (STTR [R41/R42]) grant mechanisms. The CDC and the FDA do not participate in Fast-Track, Phase II Competing Renewal applications, and the STTR program.

The purpose of this FOA from NIH is to invite eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) Phase I, Phase II, Fast-Track, and Phase II Competing Renewal grant applications through Grants.gov.  This FOA will receive funds appropriated for fiscal years (FY) 2006 and 2007, the amounts for which are yet to be determined. However, the amount set-aside by NIH for FY 2005 STTR awards was $69 million. There are three standard, annual submission dates for NIH STTR grant applications: April 1, August 1, and December 1 (May 1, September 1, and January 2 for AIDS and AIDS-related applications). For planning purposes, the NIH estimates it will make 100 STTR awards for the FY 2006 cycles. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, Fast-Track, and Phase II Competing Renewal applications, and runs in parallel with a FOA of identical scientific scope, PA-06-120, that solicits NIH, Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) applications under the Small Business Innovation Research (SBIR [R43/R44]) grant mechanisms. The CDC and the FDA do not participate in Fast-Track, Phase II Competing Renewal applications, and the STTR program.

The primary objective of this program announcement is to stimulate research on the etiology and management of sarcoidosis, a human disorder of granulomatous inflammation. We encourage research that seeks to identify not only the cause of sarcoidosis, but seeks related predisposing factors, such as genomic, proteomic, metabolomic, lipidomic or glycomic factors related to the etiology of sarcoidosis. Investigations might include how sarcoidosis perturbs the innate and acquired immunity systems; affects multi-organs within the human body; and impacts biobehavioral and psychosocial factors of the individual, family, and community. The goal is to delineate possible causes and phenotypic host characteristics in susceptible or at risk people so that preventive strategies can be developed, early diagnosis improved, and better antidotes or therapy devised to lessen initial disease immunopathology. Interventions that are cost effective and reduce the individual, family, and community burden of the disease are also encouraged. Also, there is interest for approaches to risk reduction, psychological coping, and management of complications or side effects of treatment.